A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Neratinib (Primary) ; Trastuzumab emtansine
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Nov 2019 Planned End Date changed from 1 Nov 2019 to 1 Nov 2021.
- 07 Nov 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Nov 2020.
- 07 Nov 2019 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History